Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of CX516 on Functioning in Fragile X Syndrome and Autism

This study has been completed.
Sponsor:
Collaborator:
FRAXA Foundation
Information provided by:
Cortex Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00054730
First received: February 7, 2003
Last updated: June 23, 2005
Last verified: February 2005
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given